HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $18
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Roivant Sciences (NASDAQ:ROIV) and raises the price target from $15 to $18.
June 29, 2023 | 10:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roivant Sciences' price target has been raised from $15 to $18 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Roivant Sciences. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100